Lineage Cell Therapeutics, Inc.
LCTX
$1.25
$0.086.84%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -636.02% | -26.46% | -7.88% | 47.33% | 11.95% |
| Total Depreciation and Amortization | 4.27% | 8.61% | 7.09% | -0.70% | -18.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4,315.55% | -210.63% | -125.31% | -47.23% | 2.45% |
| Change in Net Operating Assets | -777.61% | 91.12% | 18.72% | -235.02% | -19.27% |
| Cash from Operations | -13.36% | 23.01% | -9.66% | -11.80% | 10.50% |
| Capital Expenditure | 85.57% | 73.42% | -225.89% | -124.00% | -31.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -33.33% | -25.00% | 145.75% | -- |
| Cash from Investing | -100.74% | -27.78% | -32.23% | 144.22% | -23,039.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | -7.69% | 7.14% | -7.69% |
| Issuance of Common Stock | -- | -75.71% | 217,960.00% | -91.60% | -99.15% |
| Repurchase of Common Stock | -333.33% | -- | -- | -- | 100.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.79% | -286.21% | -- | -- | -- |
| Cash from Financing | -106.09% | -76.79% | 724,566.67% | -102.86% | -99.25% |
| Foreign Exchange rate Adjustments | 501.37% | -392.00% | -34.21% | 143.18% | -25.71% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -380.03% | -88.98% | 1,068.24% | 86.64% | -271.61% |